CDK9 inhibition as a potential therapeutic strategy in Ewing sarcoma

被引：0
|
作者：
Matsumura, Yuta
Heinz, Richard E.
Allred, Curtis A.
Siddiqui, Adam
Foulks, Jason M.
Warner, Steven L.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5984
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Evaluation of LDH inhibition as a treatment strategy in Ewing sarcoma
    Heske, Christine M.
    Gibson, Anna E.
    Baumgart, Josh T.
    Yeung, Choh
    Issaq, Sameer H.
    Mendoza, A.
    Johnson, Michelle S.
    Squadrito, Guiseppe L.
    Culp, Lillian
    Darley-Usmar, Victor M.
    Neckers, Len M.
    CANCER RESEARCH, 2018, 78 (19)
  • [32] Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
    Zhang, Yuming
    Shan, Lianhai
    Tang, Wentao
    Ge, Yating
    Li, Chengxian
    Zhang, Jifa
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (07) : 5185 - 5215
  • [33] THERAPEUTIC TARGETING OF PI3K AND CDK9 IN AML
    Thomas, D.
    Powell, J.
    Vergez, F.
    Barry, E. F.
    Sarry, J. E.
    Truong, N.
    Manenti, S.
    Recher, C.
    Wei, A. H.
    Guthridge, M. A.
    ANNALS OF HEMATOLOGY, 2013, 92 : S17 - S17
  • [34] Heterocyclic Compounds as CDK9 Inhibitors: Structural Diversity, Mechanism of Action, and Therapeutic Potential in Cancer and Beyond
    Bose, Kuntal
    Shajahan, Afiya
    Sreekumar, Nandana
    Aneesh, T. P.
    CHEMISTRY & BIODIVERSITY, 2025, 22 (01)
  • [35] A stitch in time and CDK9
    Cress, W. Douglas
    CELL CYCLE, 2017, 16 (09) : 823 - 824
  • [36] Understanding acquired resistance to CDK9 inhibition in hematologic tumor models
    Andersen, C.
    Proia, T.
    Cidado, J.
    Criscione, S.
    Boiko, S.
    Mills, G.
    Janne, P.
    Drew, L.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E114 - E114
  • [37] Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells
    Pandey, Somnath
    Djibo, Rahinatou
    Darracq, Anais
    Calendo, Gennaro
    Zhang, Hanghang
    Henry, Ryan A.
    Andrews, Andrew J.
    Baylin, Stephen B.
    Madzo, Jozef
    Najmanovich, Rafael
    Issa, Jean-Pierre J.
    Raynal, Noel J-M
    CANCERS, 2022, 14 (14)
  • [38] CDK9 inhibition as an effective therapy for small cell lung cancer
    Capuccino, L. Valdez
    Kleitke, T.
    Szokol, B.
    Svajda, L.
    Martin, F.
    Bonechi, F.
    Kreko, M.
    Azami, S.
    Montinaro, A.
    Wang, Y.
    Nikolov, V.
    Kaiser, L.
    Bonasera, D.
    Saggau, J.
    Scholz, T.
    Schmitt, A.
    Beleggia, F.
    Reinhardt, H. C.
    George, J.
    Liccardi, G.
    Walczak, H.
    Tovari, J.
    Braegelmann, J.
    Montero, J.
    Sos, M. L.
    Orfi, L.
    Peltzer, N.
    CELL DEATH & DISEASE, 2024, 15 (05):
  • [39] Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition
    Lai, Lick Pui
    Brel, Viviane
    Sharma, Kanika
    Frappier, Julia
    Le-Henanf, Nadia
    Vivet, Bertrand
    Muzet, Nicolas
    Schell, Emilie
    Morales, Renaud
    Rooney, Eamonn
    Basse, Nicolas
    Yi, Ming
    Lacroix, Frederic
    Holderfield, Matthew
    Englaro, Walter
    Marcireau, Christophe
    Debussche, Laurent
    Nissley, Dwight, V
    McCormick, Frank
    SLAS DISCOVERY, 2021, 26 (07) : 922 - 932
  • [40] The Aurora kinases are a potential therapeutic target in Ewing sarcoma
    Mcnae, Molly
    Roundhill, Elizabeth A.
    Burchill, Susan A.
    Bayliss, Richard W.
    CANCER RESEARCH, 2022, 82 (12)
12345